Status Offer for shares in Bionor Immuno; contemplated private placement
(Thomson Reuters ONE) - This information is subject of the disclosure requirements acc. to §5-12 vphl(Norwegian Securities Trading Act)With reference to the release 20 January and the release 12 January and theoffer document for offer to shareholders in Bionor Immuno AS (the "Offer"),Nutri Pharma ASA ("Nutri Pharma" or the "Company") announces that it hasreceived acceptances for 97,39% of the shares in Bionor Immuno AS, includingacceptances received after the end of the offer period. This implies that animportant condition under the offer so far is deemed satisfied. Based on thehigh level of support from the shareholders in Bionor Immuno AS, and to satisfya condition set out in the Offer, the Company intends to move forward to securefinancing. The Company contemplates a private placement of shares from minimumNOK 50 million to NOK 100 million with minimum subscription amount exceeding EUR50,000; where the price will be set through a book building process.Subscription period is currently planned to start 25th January and close 29thJanuary at 17:30, but may close earlier. Pareto Securities AS will be LeadManager and book runner and Orion Securities will be Co-manager. Issuance ofthe shares in the private placement will be subject to necessary corporateresolutions. Completion of the Offer is still subject to the conditions referredto in the offer, including completion of a private placement of minimum NOK 50million.FOR FURTHER INFORMATION:Trond Syvertsen, CEO +47 23 01 09 60 / + 47 91 72 14 57[HUG#1375564]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.01.2010 - 03:50 Uhr
Sprache: Deutsch
News-ID 1009194
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Oslo
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 65 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Status Offer for shares in Bionor Immuno; contemplated private placement
"
steht unter der journalistisch-redaktionellen Verantwortung von
Nutri Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
